Elite Pharmaceuticals Stock Earnings Reports

Key points for investors: Elite reported fiscal 2025 revenues of $84.0M, up 52% year-over-year, and operating income of $19.6M (up 82%), driven largely by the successful launch and initial market share capture of generic lisdexamfetamine (generic Vyvanse) plus strong performance in amphetamine IR/ER and legacy products. Lisdexamfetamine launched in Q4 and currently faces heavy competition (13+ suppliers) but Elite has already captured an estimated 8%–10% IQVIA market share; amphetamine IR (~20% share) and ER (~16% share) remain important, stable revenue sources. Cash flow from operations turned positive ($7.5M) versus a burn last year; working capital strengthened to $45.9M and total current assets rose, while debt is low and decreasing. A noncash GAAP item — change in fair value of derivatives (warrants) — produced an ~$18.9M expense this year because the stock price rose, creating a GAAP pretax loss of ~$52K despite solid operating profit; this is noncash and does not affect cash resources. The company has two ANDAs under review (including an Oxy ER Paragraph IV) and completed a successful BE for an unnamed large anticoagulant (IQVIA NSP $27B); ANDA submission for that anticoagulant is expected around Q1 2026 pending stability work and patent considerations. Manufacturing/packaging capacity expanded (34,000 sq ft packaging/inventory facility operational with two lines), supporting growth for several years. International partnership: Dexcel (Israel) has picked up initial amphetamine IR inventory and placed subsequent orders. Strategy/corporate actions: primary focus is pursuing M&A/sale (with an M&A firm identified but not yet formally engaged) before considering an uplisting to NASDAQ; management expects to evaluate Phase 1 valuation work in the coming months and will decide whether to move to active sale processes. Key risks noted: intense price/quotas competition in opioid and stimulant generics, potential patent/litigation issues for blockbuster Paragraph IV plays, API/quota shortages, and the generic market’s inherent margin pressure.